TP53 and familial pancreatic carcinoma: In line with this, two MDM2 inhibitors (MI-319 and MI-219) synergistically augmented anti-tumor effects of therapeutic drug GEM in pancreatic cancer in vitro and in vivo experimental models trough the reactivation of p53 pathway and targeting SIRT1 and Ku70 (183).